Home > Publications Database > Hypothalamic atrophy in primary lateral sclerosis, assessed by convolutional neural network-based automatic segmentation. > print

001     275878
005     20250126000509.0
024 7 _ |a 10.1038/s41598-025-85786-6
|2 doi
024 7 _ |a pmid:39789167
|2 pmid
024 7 _ |a pmc:PMC11718091
|2 pmc
024 7 _ |a altmetric:173366473
|2 altmetric
037 _ _ |a DZNE-2025-00113
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 0
245 _ _ |a Hypothalamic atrophy in primary lateral sclerosis, assessed by convolutional neural network-based automatic segmentation.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1737365650_4999
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Primary lateral sclerosis (PLS) is a motor neuron disease (MND) which mainly affects upper motor neurons. Within the MND spectrum, PLS is much more slowly progressive than amyotrophic laterals sclerosis (ALS). `Classical` ALS is characterized by catabolism and abnormal energy metabolism preceding onset of motor symptoms, and previous studies indicated that the disease progression of ALS involves hypothalamic atrophy. Very limited weight loss is observed in patients with PLS, which raises the question of whether there are also less hypothalamic alterations. The purpose of this study was to quantitatively investigate the hypothalamic volume in a group of PLS patients and to compare it with ALS and controls. Recently, we have introduced automatic hypothalamic quantification method based on the use of convolutional neural network (CNN) to reduce human variability and enhance analysis robustness. This CNN of U-Net architecture was applied for automatic segmentation of the hypothalamus and intracranial volume (ICV) to allow adjustments of the hypothalamic volume between subjects with different head sizes respectively. Automatic segmentation and volumetric analysis were performed in high resolution T1 weighted MRI volumes (acquired on a 1.5 T MRI scanner) of 46 PLS patients in comparison to 107 healthy controls and 411 `classical` ALS patients, respectively. Significant hypothalamic volume reduction was observed in PLS (818 ± 73 mm3) when compared to controls (852 ± 77 mm3); significant hypothalamic volume reduction was also confirmed in ALS (823 ± 84 mm3), in support of previous studies. No significant differences were found in normalized hypothalamic volumes between ALS patients and PLS patients at the group level. This unbiased CNN-based hypothalamus volume quantification study demonstrated similarly reduced hypothalamus volume in PLS and ALS patients, despite the clinical phenotypic differences.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyotrophic Lateral Sclerosis
|2 Other
650 _ 7 |a Hypothalamus
|2 Other
650 _ 7 |a Magnetic Resonance Imaging
|2 Other
650 _ 7 |a Metabolism
|2 Other
650 _ 7 |a Neuronal Networks
|2 Other
650 _ 7 |a Primary Lateral Sclerosis
|2 Other
650 _ 7 |a Volumetry
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Hypothalamus: pathology
|2 MeSH
650 _ 2 |a Hypothalamus: diagnostic imaging
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neural Networks, Computer
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Atrophy: pathology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: pathology
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: diagnostic imaging
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Motor Neuron Disease: pathology
|2 MeSH
650 _ 2 |a Motor Neuron Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Image Processing, Computer-Assisted: methods
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
700 1 _ |a Roselli, Francesco
|0 P:(DE-2719)2812851
|b 1
700 1 _ |a Witzel, Simon
|b 2
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 3
|u dzne
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 4
|u dzne
700 1 _ |a Rasche, Volker
|b 5
700 1 _ |a Vernikouskaya, Ina
|b 6
700 1 _ |a Müller, Hans-Peter
|b 7
773 _ _ |a 10.1038/s41598-025-85786-6
|g Vol. 15, no. 1, p. 1551
|0 PERI:(DE-600)2615211-3
|n 1
|p 1551
|t Scientific reports
|v 15
|y 2025
|x 2045-2322
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/275878/files/DZNE-2025-00113.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/275878/files/DZNE-2025-00113.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:275878
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9001967
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2812851
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812633
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-29T15:28:26Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)1910001
|k AG Roselli
|l Metabolic Changes in Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1910001
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21